Inspectorate

AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

Retrieved on: 
Monday, December 12, 2022
Science, Degenerative disease, MPS, MD, Toxicity, Science Translational Medicine, West Chester University, Disulfiram-like drug, Multi, Research, COVID-19, Biomedical sciences, Central Florida, EAP, SBIR, Rintatolimod, Erasmus MC, Metabolic syndrome, Blog, Science education, Inspectorate, Manuscript, Senior, Publication, Therapy, Molecular biology, Chronic fatigue syndrome, CFS, Special access program, University of Central Florida, Heart, AIM, Neuromuscular Disorders, IPSC, NIH, ISCB Senior Scientist Award, University, Immune system, Disease, Tissue, Patient, Sarcopenia, Chief scientific officer, NYSE, Pancreatic cancer, Microbiology, Physician, ME/CFS, PSLRA, Cancer, Vaccine, Management, Pharmaceutical industry, Chemistry, Hesperus, Biology

OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the promotion of Christopher McAleer, Ph.D., from Deputy Scientific Officer to Scientific Officer.

Key Points: 
  • OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the promotion of Christopher McAleer, Ph.D., from Deputy Scientific Officer to Scientific Officer.
  • Chris will make an excellent Scientific Officer,” said David Strayer, MD, AIM’s Chief Scientific and Medical Officer.
  • We are pleased to deepen his role with his appointment as Scientific Officer as we continue to advance our pipeline forward.
  • Additionally, Dr. McAleer has authored published manuscripts in several peer-reviewed science and nature journals, book chapters and scientific conference publications.

AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Retrieved on: 
Thursday, December 8, 2022
Smallpox vaccine, Event, RNA, B cell, Immunology, Society, Chronic fatigue syndrome, CFS, Special access program, EAP, NYSE, Influenza and Other Respiratory Viruses, Pancreatic cancer, RANTES, AES, British Society for Research on Ageing, Safety, Physician, Monocyte, AIM, Degenerative disease, Erasmus MC, TNF, Vaccinia, IL-8, Chemokine, Inspectorate, ME/CFS, TLR3, PSLRA, IL-6, Infection, Patient, CXCL10, Immune system, Research, Disease, Interferon, Cancer, Severe acute respiratory syndrome coronavirus 2, COVID-19, CHDR, Granulocyte, Therapy, Vaccine, Pharmaceutical industry, Rintatolimod, MCP-1

OCALA, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported that data were recently presented by Lisanne C.A. Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 . The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.

Key Points: 
  • Smidt - Centre for Human Drug Research (CHDR), Leiden, the Netherlands in a poster titled, “Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects,” at the British Society for Immunology Congress 2022 .
  • The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.
  • Intranasal administration of Ampligen could induce an innate mucosal immune response, thereby inhibiting respiratory viruses at the point of entry.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
Friday, December 2, 2022
NYSE, Immunology, EAP, CFS, Congress, COVID-19, Degenerative disease, Society, Special access program, PSLRA, Erasmus MC, ME/CFS, Research, Cancer, AIM, Therapy, Inspectorate, Patient, Pancreatic cancer, Disease, British Society for Neuroendocrinology, Chronic fatigue syndrome, Rintatolimod, Immune system, Pharmaceutical industry

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

AIM ImmunoTech Announces Corporate Governance Enhancements

Retrieved on: 
Wednesday, November 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Professional Football Compensation Committee, AIM, AIM ImmunoTech, NYSE, Optimism, U.S. Securities and Exchange Commission, Pancreatic cancer, Committee, ME/CFS, Annual general meeting, Food, Chronic fatigue syndrome, Knowledge, Research, Risk, Erasmus MC, Financial compensation, Association, Board, COVID-19, Degenerative disease, CFS, Special access program, Survival, FOLFIRINOX, American Association, Company, Form 10-K, Independent, Ovarian cancer, Patient, Breast cancer, Immune system, Therapy, Security (finance), Inspectorate, Cisplatin, EAP, FDA, American Association for Cancer Research, Management, Pharmaceutical industry, Rintatolimod, Facebook, Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:
    The Governance and Nominating Committee of the AIM Board of Directors (the Board) has initiated a process to add two directors who bring diversity and additional biotechnology commercialization experience to the Board.
  • The corporate governance enhancements we are announcing today are designed to further strengthen our Board through the addition of new independent directors with in-depth knowledge of biotechnology commercialization and diverse backgrounds, and to further align the Companys leadership with AIMs performance and the best interests of all shareholders.
  • Mitchell continued: Over the past year AIM ImmunoTech has made significant progress achieving multiple clinical and regulatory advances.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Company, AIM, Research, Therapy, Degenerative disease, EAP, Risk, Rintatolimod, Form 10-K, Inspectorate, NYSE, Optimism, Erasmus MC, COVID-19, ME/CFS, CFS, Pancreatic cancer, U.S. Securities and Exchange Commission, Cancer, Immune system, Medi-Cal Access Program, Security (finance), Chronic fatigue syndrome, Patient, Public relations, Pharmaceutical industry, Facebook

AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that shareholders have re-elected all three of the Companys directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Companys Annual Meeting of Shareholders (the Annual Meeting) held today.

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that shareholders have re-elected all three of the Companys directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Companys Annual Meeting of Shareholders (the Annual Meeting) held today.
  • AIM issued the following statement:
    We are grateful to our shareholders for their support and engagement.
  • The Company will file the final voting results on a Form 8-K with the Securities and Exchange Commission.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Retrieved on: 
Wednesday, November 2, 2022
AIM, Inspectorate, Vaccinia, ME/CFS, Ebola, Pancreatic cancer, Chronic fatigue syndrome, Food and Drug Administration, GLOBE, Research, NYSE, Degenerative disease, COVID-19, Program, Disease, Orphan drug, Special access program, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, Erasmus MC, EVD, EAP, Safety, Condition, Company, Centers for Disease Control and Prevention timeline, Cancer, FDA, Patient, Food, American, CFS, ACHES, Fever, Smallpox vaccine, CDC, Severe acute respiratory syndrome coronavirus 2, Therapy, AIM ImmunoTech, Diagnosis, Vaccine, Pharmaceutical industry, Rintatolimod

OCALA, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ampligen® (rintatolimod) for the treatment of Ebola virus disease.

Key Points: 
  • Ampligen is AIMs dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen.
  • We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need.
  • Ebola virus disease (EVD) is a rare but severe, deadly disease causing a multitude of symptoms including fever, gastrointestinal issues, aches, and bruising.1 Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1.

AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

Retrieved on: 
Tuesday, August 30, 2022
COVID-19, National Cancer Institute, Cell, Research, AIM, PSLRA, GLOBE, ORR, Company, Patient, Cancer, OS, Hope, Upstate New York, Rintatolimod, Chronic fatigue syndrome, Degenerative disease, Progression-free survival, Roswell Park Comprehensive Cancer Center, Lists of diseases, Interferon, PFS, Tumor microenvironment, Disease, Myalgia, NCI, American, Private Securities Litigation Reform Act, Inspectorate, RECIST, HIV disease progression rates, FACP, NYSE, Pancreatic cancer, Celecoxib, Doctor of Philosophy, RNA, ME/CFS, Access, Immune system, Therapy, Clinical trial, Erasmus MC, National, Vaccine, Pharmaceutical industry, MSCI, Melanoma, MD

OCALA, Fla., Aug. 30, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its clinical development collaborator, Roswell Park Comprehensive Cancer Center (“Roswell Park”), in a clinical trial fully funded by the National Cancer Institute (NCI), has commenced patient enrollment in its Phase 2 study in subjects with primary PD-1/PD-L1 resistant melanoma. The Phase 2 study will evaluate type-1 polarized dendritic cell (αDC1) vaccine in combination with tumor-selective chemokine modulation (“CKM”) comprised of Interferon alpha 2b, Ampligen (rintatolimod) and Celecoxib.

Key Points: 
  • The Phase 2 study will evaluate type-1 polarized dendritic cell (DC1) vaccine in combination with tumor-selective chemokine modulation (CKM) comprised of Interferon alpha 2b, Ampligen (rintatolimod) and Celecoxib.
  • The start of this NCI-funded clinical trial marks an important milestone for our Melanoma R&D program.
  • Ampligen (rintatolimod) is AIMs dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • The trial will be conducted at Roswell Park under the clinical leadership of Igor Puzanov, MD, MSCI, FACP , Chief of Melanoma at Roswell Park, and the overall scientific leadership of Pawel Kalinski, MD, PhD , Roswell Park Chair of Immunology.

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, August 18, 2022
Survival, CEO, GLOBE, Clinical trial, Cancer, Research, Marketing, Patient, Institutional review board, Food, Immune system, Erasmus, Disease, Access, Safety, Erasmus MC, Private Securities Litigation Reform Act, Nebraska Medicine, American, IRB, Regulatory affairs, Contract research organization, Monitoring, Data management, University of Nebraska Medical Center, Chronic fatigue syndrome, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRO, LLC, COVID-19, AIM, FDA, NYSE, Inspectorate, ME/CFS, Lists of diseases, Biomedical Research, LAPC, Company, Pancreatic cancer, Therapy, Myalgia, Degenerative disease, PSLRA, FOLFIRINOX, University, Human, NSF International, Pharmaceutical industry, Vaccine, Rintatolimod, Pharmacovigilance

OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.

Key Points: 
  • AIM Chief Executive Officer Thomas K. Equels commented, We are pleased to reach this important step in the development of Ampligen.
  • Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of LAPC is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer.
  • The Companys Phase 2 study Investigational New Drug (IND) application was previously cleared by the U.S. Food and Drug Administration (FDA).
  • The AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma.

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

Retrieved on: 
Monday, August 15, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NUALS Arts and Literary Annual Meet, U.S. Securities and Exchange Commission, Risk, Erasmus MC, Name, NYSE, Inspectorate, Delaware Court of Chancery, Annual general meeting, SEC, Board, Lists of diseases, Hearing, Research, Optimism, Security (finance), Cancer, EAP, Beneficial ownership, Court, Patient, COVID-19, Company, Twitter, Pancreatic cancer, American, Therapy, Form 10-K, CFS, Special access program, Degenerative disease, Rintatolimod, Delaware Court, WHEN, LinkedIn, Chronic fatigue syndrome, AIM, THE, Immune system, Pharmaceutical industry, Ownership, Facebook, Shareholder

The Court of Chancery reconvened the hearing today and denied Mr. Jorgls motion for a TRO.

Key Points: 
  • The Court of Chancery reconvened the hearing today and denied Mr. Jorgls motion for a TRO.
  • The Court scheduled a hearing on Mr. Jorgls motion for a preliminary injunction to be held on October 5, 2022.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Companys lead product, Ampligen (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Retrieved on: 
Thursday, July 28, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Erasmus MC, Long COVID, CFS, Brain, Time, Nursing, Lists of diseases, PASC, Inspectorate, Food, Chronic fatigue syndrome, Pancreatic cancer, Research, Poly, AIM, Fatigue, Private Securities Litigation Reform Act, Degenerative disease, Family, Immune system, Access, Exercise, FDA, Company, Cancer, Patient, COVID, PSLRA, Post-exertional malaise, Therapy, Chronic fatigue, IND, Pharmaceutical industry, COVID-19, Rintatolimod

We remain committed to advancing development of Ampligen as a therapeutic for the treatment of Long COVID or Post-Acute Sequelae of Covid (PASC) and look forward to further evaluating its potential.

Key Points: 
  • We remain committed to advancing development of Ampligen as a therapeutic for the treatment of Long COVID or Post-Acute Sequelae of Covid (PASC) and look forward to further evaluating its potential.
  • Based in part on these early positive data, AIM is continuing to work toward filing an IND application with the FDA for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions.
  • The first subject fulfilled the current criteria for long COVID disease and had no contraindications.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.